Kowal Investment Group’s AstraZeneca AZN Stock Holding History

Kowal Investment Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-27	Closed	-$3K	–	193
2021 Q3	$3K	Buy	+27	New	+$3.14K	﹤0.01%	723

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kowal Investment Group's AZN Position: Q4 2021 in Review

Kowal Investment Group sold out of AstraZeneca (AZN) in Q4 2021, closing a stake of 27 shares — an estimated $3K sold.

Kowal Investment Group first reported a position in AZN in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 949 funds tracked by Wall St. Rank hold AZN as of Q4 2021.

Kowal Investment Group reported no remaining AstraZeneca position as of Q4 2021 after selling out during the quarter.
Kowal Investment Group sold 27 AstraZeneca shares in Q4 2021, an estimated $3K.
Kowal Investment Group first reported a position in AstraZeneca in Q3 2021 and held it in 1 quarter.
Kowal Investment Group's AstraZeneca position peaked at $3K in Q3 2021.
949 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.

Based on Kowal Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.